PLGA (lactide/glycolide ratio of 50:50) (Resomer RG 503, Boehringer, Germany) with a molecular weight of 24–38 kDa was used in the fabrication of membranes. Vildagliptin (C17H25N3O2) and hexafluoroisopropanol (HFP) were obtained (Sigma-Aldrich, Saint Louis, MO, USA) and mixed for the following products.
Vildagliptin-eluting nanofibrous PLGA membranes (vildagliptin, 40 mg; PLGA, 240 mg; HFP: 1000 µL) and drug-free PLGA membranes (PLGA, 280 mg; HFP: 1000 µL) were fabricated at around 25 °C using the especially designed electrospinning setup [50 (link)]. During electrospinning, the needle with an inside diameter of 420 nm had a high-voltage direct current connection (35 kV and 4.16 mA). The electrospun voltage was 35 kV, feed rate was 3.6 mL/h, and tip to collector distance was 120 mm. The electrospun products were kept in a vacuum drying oven at 40 °C for three days to evaporate HFP.
Vildagliptin-eluting nanofibrous PLGA membranes (vildagliptin, 40 mg; PLGA, 240 mg; HFP: 1000 µL) and drug-free PLGA membranes (PLGA, 280 mg; HFP: 1000 µL) were fabricated at around 25 °C using the especially designed electrospinning setup [50 (link)]. During electrospinning, the needle with an inside diameter of 420 nm had a high-voltage direct current connection (35 kV and 4.16 mA). The electrospun voltage was 35 kV, feed rate was 3.6 mL/h, and tip to collector distance was 120 mm. The electrospun products were kept in a vacuum drying oven at 40 °C for three days to evaporate HFP.
Free full text: Click here
